Recent developments in nuclear medicine include radiolabelled PSMA‐ligands for prostate cancer (e.g. [68Ga]Ga‐PSMA‐11, [18F]PSMA‐1007 or [18F]DCFPyL used for diagnostics and [177Lu]Lu‐PSMA‐617 for therapy) (Ahmadzadehfar et al., 2016; Ferdinandus et al., 2017; Hofman et al., 2018; Kabasakal et al., 2015; Yordanova et al., 2017). The gene discussed is FOLH1; the disease is prostate carcinoma.